The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction – baseline. failure.9 A trial of ivabradine involving patients well as for the fidelity of this report to the trial tricular systolic dysfunction (BEAUTIFUL). The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction.

Author: Golticage Faegami
Country: Luxembourg
Language: English (Spanish)
Genre: Education
Published (Last): 22 July 2016
Pages: 316
PDF File Size: 16.56 Mb
ePub File Size: 19.53 Mb
ISBN: 443-7-33704-213-6
Downloads: 92227
Price: Free* [*Free Regsitration Required]
Uploader: Goltigor

Neither of the above. Register Already registered with FPrime?


F does not store recipient email addresses. Patients may take ivabradine in combination with standard therapy, including beta blockers, or when beta blocker therapy is contraindicated or not tolerated. Examples of ‘Financial Competing Interests’ You expect to receive, or in the past 4 years have received, any of the following from any commercial organization that may gain financially from your submission: Administration The recommended starting dose of ivabradine is 5 mg by mouth twice daily with meals.

I am an author of this article. This entry form currently does not support special characters. The mean heart rate in these patients was 71 bpm and half of the patients had a heart rate more than 70 bpm.


I am a Faculty Member who recommended this article. Given that the number of open channels directly correlates with heart rate, the actions of ivabradine are considered “rate-dependent” and the triaal reduction of heart rate is a function of heart rate at baseline.

Patients assigned to ivabradine were started on 5 mg twice daily and the dose was modified according to the heart rate, which was assessed in 2 weeks. Binding and un-binding of ivabradine at the channel site only occurs when the channel is in an “open” state. Read your latest personalised notifications Sign in No account yet?


By posting Material you grant to F an irrevocable non-exclusive royalty-free license to keep a copy of Material for a reasonable period and as necessary to enable it to comply with its legal obligations. Reduction in heart rate with ivabradine does not improve cardiac outcomes in all patients with stable coronary artery disease and left-ventricular systolic dysfunction, but could be used to reduce the incidence of coronary artery disease outcomes in tria subgroup of patients who have heart rates of 70 bpm or greater.

These terms shall be governed by and construed in accordance with English Law. Classified as close Confirmation 1. In a prespecified subgroup of patients with heart rate of 70 bpm or greater, ivabradine treatment did not affect the primary composite outcome hazard ratio 0. Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable beautoful to question your impartiality.

The dose of beta blockers was maintained during the trial; no reduction in dosage was observed while titrating frial. Ivabradine reduced heart rate by 6 bpm SE 0. Sign in to My ESC.

We analysed patients by intention to treat. Certain parts of this website offer the opportunity for users to post opinions, information and material including without limitation academic papers and data ‘Material’ in areas of the website.


However, beta blockers have undesirable adverse effects i. However, it did reduce secondary endpoints: ESC sub specialties communities. You may not use the website for any unlawful purpose, including without limitation, to upload, post, download or otherwise use any Material that you do not have the copyright owners permission to so upload, post, download or otherwise use, or ivabadine would result in you being in breach of these terms and conditions.

With the BEAUTIFUL Results, Procoralan* (ivabradine) is the First Antianginal Tr

Between December,and December,we screened 12 patients at centres in 33 countries. However, it did reduce secondary endpoints: You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You are a close professional associate of any of ivabraidne authors e.

A summary of the content will be automatically included. Accordingly you may only post Material that you have the right to do so. Institutional access Recommend FPrime to your librarian or information manager to request an extended free trial for all users at your institution. Powered By Decision Support beauutiful Medicine.

The study is registered with ClinicalTrials. Examples of ‘Non-Financial Competing Interests’ Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.

Author: admin